Zentalis Pharmaceuticals, Inc. (ZNTL)
| Market Cap | 185.56M +68.1% |
| Revenue (ttm) | n/a |
| Net Income | -139.55M |
| EPS | -1.96 |
| Shares Out | 94.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,332,472 |
| Open | 1.990 |
| Previous Close | 1.990 |
| Day's Range | 1.860 - 1.990 |
| 52-Week Range | 1.212 - 6.950 |
| Beta | 1.94 |
| Analysts | Buy |
| Price Target | 7.33 (+274.13%) |
| Est. Earnings | Nov 13, 2026 |
About ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ZNTL stock is "Buy." The 12-month stock price target is $7.33, which is an increase of 274.13% from the latest price.
News
Zentalis price target lowered to $7 from $8 at Mizuho
Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Zentalis (ZNTL) to $7 from $8 and keeps an Outperform rating on the shares.
Zentalis announces median OS data from DENALI Part 1b study
Zentalis (ZNTL) presented results from an interim analysis of the DENALI Part 1b study as of a May 22 data cutoff, including the first overall survival analysis for azenosertib, at…
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhib...
Zentalis announces first OS data from DENALI part 1b study
Zentalis (ZNTL) Pharmaceuticals announced that overall survival, OS, data from an interim analysis of the DENALI Part 1b study, GOG-3066, have been published in the abstract for the upcoming rapid…
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
SAN DIEGO, Oct. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhib...
Zentalis assumed at Outperform from Market Perform at Leerink
Leerink upgraded Zentalis (ZNTL) to Outperform from Market Perform with a price target of $8, up from $4, while assuming coverage of the stock. The analyst, who thinks the market…
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhib...
Zentalis initiated with an Outperform at William Blair
William Blair initiated coverage of Zentalis (ZNTL) with an Outperform rating. The firm cites the potential of the company’s WEE1 inhibitor azenosertib to deliver a clinically meaningful overall respo...
Zentalis Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Azenosertib is advancing in late-stage trials for platinum-resistant ovarian cancer, with strong FDA support and a differentiated safety profile. Expansion into earlier lines and other tumor types is under evaluation, while commercial and financial preparations ensure readiness for upcoming data and potential launch.
Zentalis Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
Key clinical trials for azenosertib in platinum-resistant ovarian cancer are progressing, with robust safety oversight and a validated biomarker strategy. The drug is positioned as a differentiated, non-chemo oral option, with global regulatory alignment and a strong financial runway supporting ongoing development.
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhi...
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investig...
Zentalis announecs common stock offering, no amount given
Zentalis (ZNTL) Pharmaceuticals announced the commencement of a proposed underwritten public offering of shares of its common stock and in lieu of common stock to certain investors that so choose,…
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investig...
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investig...
Zentalis price target raised to $5 from $4 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Zentalis (ZNTL) to $5 from $4 and keeps an Equal Weight rating on the shares.
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates
Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2 Enrollment completed in Part 2a and 2b of the DENALI trial; Part 2c is enrolling DENALI ...
Zentalis Pharmaceuticals Quarterly report: Q2 2026
Zentalis Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Zentalis Pharmaceuticals Earnings release: Q2 2026
Zentalis Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Zentalis Pharmaceuticals Slides: Corporate presentation
Zentalis Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Zentalis initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Zentalis (ZNTL) with a Buy rating and $11 price target The firm cites the commercial potential of azenosertib, a potentially first-in-class WEE1 inhibitor target...
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a c...
Zentalis initiated with an Outperform at Mizuho
Mizuho analyst Graig Suvannavejh initiated coverage of Zentalis (ZNTL) with an Outperform rating and $8 price target The firm sees an attractive-risk reward ahead of the Phase 2 DENALI Part…
Zentalis assumed with an Outperform at Oppenheimer
Oppenheimer assumed coverage of Zentalis (ZNTL) with an Outperform rating and $9 price target The company is entering an important period with registrational DENALI data expected by year-end, the firm...
Zentalis Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
Azenosertib is advancing as a differentiated therapy for platinum-resistant ovarian cancer, showing strong efficacy and tolerability in cyclin E1 high patients, with promising results in combination with paclitaxel and ongoing expansion into PARP progressor populations. External interest in combination strategies is high, with new studies expected post-2025.